ViraCyte Receives Orphan Drug Designation for Viralym-C

ViraCyte, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Viralym-C, a ready to administer T cell immunotherapy product for the treatment of cytomegalovirus (CMV) in severely immunocompromised patients.

ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C

ViraCyte, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Viralym-C, ViraCyte's T cell immunotherapy product designed to treat refractory cytomegalovirus (CMV) infections in patients following a stem cell transplant.

ViraCyte Announces Oral Presentations on Clinical Trial Results at the 58th American Society of Hematology Annual Meeting

ViraCyte, LLC announced today that two abstracts regarding the Company's lead product candidates, Viralym-C and Viralym-M, were selected for oral presentations at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California on December 3-6.

ViraCyte Appoints Dr. Brett Giroir as President and Chief Executive Officer

ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today announced the appointment of Brett P. Giroir, M.D. as President and Chief Executive Officer, effective immediately.

ViraCyte Selected as a Resident Company at JLABS @ TMC

Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston